SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 49 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,787,000 | +16.6% | 150,000 | 0.0% | 0.07% | +3.1% |
| Q2 2018 | $1,532,000 | -21.3% | 150,000 | 0.0% | 0.06% | -29.7% |
| Q1 2018 | $1,947,000 | +33.4% | 150,000 | 0.0% | 0.09% | +19.7% |
| Q4 2017 | $1,460,000 | -33.9% | 150,000 | 0.0% | 0.08% | -39.2% |
| Q3 2017 | $2,208,000 | -8.5% | 150,000 | 0.0% | 0.12% | -16.7% |
| Q2 2017 | $2,414,000 | +1.0% | 150,000 | 0.0% | 0.15% | -5.1% |
| Q1 2017 | $2,390,000 | +31.0% | 150,000 | 0.0% | 0.16% | +32.8% |
| Q4 2016 | $1,824,000 | -12.3% | 150,000 | 0.0% | 0.12% | -6.3% |
| Q3 2016 | $2,081,000 | -23.6% | 150,000 | 0.0% | 0.13% | -24.0% |
| Q2 2016 | $2,723,000 | – | 150,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,539,895 | $11,540,000 | 4.03% |
| Bain Capital Life Sciences Investors, LLC | 6,264,420 | $20,422,000 | 1.62% |
| Samsara BioCapital, LLC | 2,189,199 | $6,243,000 | 1.21% |
| Omega Fund Management, LLC | 2,512,705 | $8,191,000 | 1.16% |
| Altium Capital Management LP | 1,160,000 | $3,782,000 | 1.04% |
| Sio Capital Management, LLC | 900,677 | $2,936,000 | 0.88% |
| Artal Group S.A. | 3,000,000 | $9,780,000 | 0.26% |
| Flagship Pioneering Inc. | 2,938,494 | $9,579,000 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 242,132 | $789,000 | 0.10% |
| Orbimed Advisors | 1,837,500 | $5,990,000 | 0.08% |